US 12,269,809 B2
5-hydroxytryptamine receptor 7 activity modulators and their method of use
Daniel J. Canney, Ambler, PA (US); Benjamin E. Blass, Eagleville, PA (US); Rong Gao, Eugene, OR (US); and Magid Abou-Gharbia, Exton, PA (US)
Assigned to Temple University-Of The Commonwealth System of Higher Education, Philadelphia, PA (US)
Filed by Temple University-Of The Commonwealth System of Higher Education, Philadelphia, PA (US)
Filed on Nov. 2, 2021, as Appl. No. 17/517,166.
Application 16/712,711 is a division of application No. 15/510,152, granted, now 10,544,117, issued on Jan. 28, 2020, previously published as PCT/US2015/049303, filed on Sep. 10, 2015.
Application 17/517,166 is a continuation of application No. 16/712,711, filed on Dec. 12, 2019, granted, now 11,192,871.
Claims priority of provisional application 62/048,476, filed on Sep. 10, 2014.
Prior Publication US 2022/0306596 A1, Sep. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 405/06 (2006.01); C07D 307/28 (2006.01); C07D 307/33 (2006.01); C07D 307/94 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01)
CPC C07D 307/33 (2013.01) [C07D 307/28 (2013.01); C07D 307/94 (2013.01); C07D 405/06 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01)] 21 Claims
 
1. A compound having formula (II):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1a and R1b are each independently a C1-6 linear alkyl;
R3 is selected from a group consisting of 1H-benzo[d]imidazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 1H-indole, optionally substituted pyridin-2-yl, optionally substituted pyridin-3-yl, and optionally substituted pyridin-4-yl; and
n is 1, 2, or 3.